查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018686

被忽視的熱帶疾病治療市場：2026-2032年全球市場預測（按藥物類型、疾病、給藥途徑、治療方法、最終用戶和分銷管道分類）

Neglected Tropical Disease Treatment Market by Drug Type, Disease Indication, Route Of Administration, Treatment Approach, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

被忽視的熱帶疾病治療市場預計到 2025 年將達到 68.3 億美元，到 2026 年將成長到 72.9 億美元，到 2032 年將達到 107.9 億美元，複合年成長率為 6.74%。

主要市場統計數據
基準年 2025 68.3億美元
預計年份：2026年 72.9億美元
預測年份 2032 107.9億美元
複合年成長率 (%) 6.74%

策略架構涵蓋優先事項、實施挑戰以及對綜合公共衛生干預措施的需求，以期在被忽視的熱帶疾病治療中取得永續的成果。

被忽視的熱帶疾病在許多中低收入國家仍是一項重大的公共衛生挑戰，需要臨床、後勤和政策等各部門協調應對。近年來，環境變化、人口遷移和醫療衛生系統能力的提升等因素從根本上改變了治療性介入的優先順序和實施方式。因此，包括公共衛生機構、非政府組織、醫療服務提供者和製藥公司相關人員必須協調各自的策略，以維持治療效果、擴大覆蓋範圍並維護社區信任。

科學進步、流行病學變化和不斷演變的採購模式如何重新定義被忽視的熱帶疾病的治療範式和供應鏈韌性。

被忽視的熱帶疾病治療模式正經歷變革性的轉變，這主要得益於科學創新、人口壓力和政策環境的轉變。診斷靈敏度的提高和即時檢測技術的進步正在縮小臨床發現與及時治療之間的差距，使得在傳統的大規模藥物宣傳活動之外，能夠進行更具標靶治療。同時，藥物研發管線也不斷多元化，涵蓋了最佳化的驅蟲藥、聯合治療以及具有簡化給藥方案的再利用抗生素，這些方案可在資源匱乏的環境中實施。

2025 年美國關稅調整將導致整體治療產業的供應鏈、籌資策略和庫存計畫重組，進而對營運和採購產生累積影響。

2025年關稅徵收和貿易政策變化對被忽視的熱帶疾病（NTD）項目所需基本治療藥物的採購趨勢和供應鏈結構產生了重大影響。活性藥物成分和製劑組分關稅的增加推高了某些藥物類別的到貨成本，促使採購負責人重新審視其供應商組合，並儘可能優先考慮本地生產。為此，供應鏈經理加快了對替代供應商進行認證、拓展物流路線以及加強區域內合約的步伐，為未來的政策變化做好準備。

針對不同適應症，透過協調需求、治療領域、通路和給藥方法，最佳化專案實施，應對細分市場主導的臨床和採購挑戰。

要精準了解市場，需要根據適應症、產品分類、供應鏈、終端用戶環境、給藥途徑和治療方法進行細分，這些因素指南臨床決策和營運設計。在考慮登革熱、淋巴絲蟲病、盤尾絲蟲病、血吸蟲病和沙眼等疾病的適應症時，各項目的優先事項有顯著差異。登革熱的防治活動著重於病媒控制和快速臨床治療，而淋巴絲蟲病和盤尾絲蟲病的防治活動則著重於大規模用藥和發病率管理。血吸蟲病干預措施強調以學校和社區為基礎的化療，而沙眼防治計畫則整合了抗生素分發、臉部衛生和環境干預措施。

美洲、歐洲、中東和非洲以及亞太地區的區域實際情況和流行病學細微差別決定了適應性治療策略和供應選擇。

區域環境對專案優先事項、監管應對措施和夥伴關係模式有顯著影響。美洲、歐洲、中東、非洲和亞太地區各自面臨不同的流行病學模式和運作限制。在美洲，都市化趨勢和醫療能力的差異決定了兩個關鍵優先事項：應對蟲媒病毒疫情和持續進行以社區為基礎的蠕蟲感染疾病防治措施。該地區的計畫實施者通常優先考慮與基層醫療平台整合，並利用當地健康網路擴大支援範圍。

製藥公司、供應商和服務供應商如何透過配方創新、在地化生產和增強分銷能力來重新定義其競爭優勢。

產業相關人員和公共部門合作夥伴正在適應新的情況，在這種情況下，臨床療效、監管靈活性和物流能力正在決定競爭地位。專注於驅蟲藥和抗生素的製藥公司正在投資研發簡化配方和兒童片劑，以方便高劑量給藥並提高患者的用藥依從性。同時，抗節肢動物藥物和殺蟲劑供應商正在調整其配方，使其與綜合病媒控制方案相契合，並將安全性和環境因素放在首位。隨著相關人員努力減少對漫長國際供應鏈的依賴，並更靈活地應對區域需求波動，契約製造和本地生產設施的戰略重要性日益凸顯。

領導者可採取切實可行的策略步驟，以增強專案韌性，加速服務獲取，並使採購和臨床策略與當地營運實際情況相符。

產業領導者和公共衛生官員可以透過將策略性投資與實際營運情況和臨床優先事項相結合，來提高策略性投資的有效性。首先，應優先考慮能夠簡化給藥方式並提高社區接受度的製劑和給藥途徑創新。這可以減少對先進臨床基礎設施的依賴，並支持在大規模藥物管理中實現更高的覆蓋率。其次，應加強本地供應商網路，並投資於本地製造夥伴關係，以降低貿易政策風險，縮短前置作業時間，並確保品管系統能夠維護產品的完整性。

透明的調查方法，將臨床文獻、實施評估、監管分析和相關人員訪談結合，從而得出基於真實世界證據的操作性結論。

本報告整合了來自同行評審的臨床文獻、專案實施報告、監管公告以及與採購負責人、臨床醫生和供應鏈專家等相關人員訪談的多項證據。資料整合的優先順序著重於近期關於治療效果和安全性的同儕審查研究、大規模藥物宣傳活動實施情況的評估以及貿易和採購政策的記錄變更。來自第一線負責人和生產合作夥伴的定性見解也被納入對營運可行性和供應鏈動態的評估中，從而為技術見解提供了現實世界的背景。

整合策略重點，強調以社區為基礎的綜合能力和數據驅動的專案設計，以持續推進被忽視的熱帶病防治工作。

總之，被忽視的熱帶疾病治療格局正處於轉折點，要取得持續進展，需要臨床技術的進步、供應鏈的現代化以及適應性政策的共同作用。有效的計畫應將大規模藥物管理與有針對性的臨床干預相結合，並輔以更強大的區域生產能力、更先進的診斷技術以及能夠提升供應鏈應對力的數位化工具。此外，製劑創新和以社區為中心的給藥系統對於擴大覆蓋範圍、同時確保安全性和可接受性至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 被忽視的熱帶疾病治療市場（按藥物類型分類）

  • 驅蟲
    • 阿苯達唑
    • 伊維菌素
    • 甲苯咪唑
  • 節肢動物滅殺者
  • 抗生素
    • 阿奇黴素
    • 多西環素
  • 原生動物治療藥物
    • 惠明
    • 噴他脒
    • 蘇拉明
  • 殺蟲劑

第9章：被忽視的熱帶疾病治療市場：依疾病適應症分類

  • 登革熱
  • 淋巴絲蟲病
  • 盤尾絲蟲病
  • 血吸蟲病
  • 沙眼

第10章：被忽視的熱帶疾病治療市場：依給藥途徑分類

  • 口服
  • 腸外
  • 外用

第11章 被忽視的熱帶疾病治療市場：依治療方法分類

  • 團體用藥
  • 標靶治療

第12章：被忽視的熱帶疾病治療市場：依最終用戶分類

  • 診所
  • 社區健康中心
  • 醫院
  • 行動診所

第13章：被忽視的熱帶疾病治療市場：依分銷管道分類

  • 政府項目
  • 醫院藥房
  • 非政府組織分發
  • 零售藥房

第14章 被忽視的熱帶疾病治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：被忽視的熱帶疾病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 被忽視的熱帶疾病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國被忽視的熱帶疾病治療市場

第18章：中國被忽視的熱帶疾病治療市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • Hansa Biopharma AB
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-AD36CD897E7F

The Neglected Tropical Disease Treatment Market was valued at USD 6.83 billion in 2025 and is projected to grow to USD 7.29 billion in 2026, with a CAGR of 6.74%, reaching USD 10.79 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.83 billion
Estimated Year [2026] USD 7.29 billion
Forecast Year [2032] USD 10.79 billion
CAGR (%) 6.74%

A strategic framing of neglected tropical disease treatment priorities, delivery challenges, and the imperative for integrated public health interventions that drive sustained outcomes

Neglected tropical diseases remain a defining public health challenge in many low- and middle-income settings, demanding coordinated clinical, logistical, and policy responses. In recent years, the confluence of environmental change, population movements, and evolving health system capacities has reshaped how treatment interventions are prioritized and delivered. Consequently, stakeholders across public health agencies, non-governmental organizations, clinical providers, and pharmaceutical manufacturers must align their approaches to preserve treatment efficacy, extend reach, and sustain community trust.

This analysis introduces the current treatment landscape by situating core clinical interventions within broader delivery and regulatory contexts. It emphasizes the need for integrated strategies that bridge mass drug administration approaches with targeted therapies, while recognizing the role of primary care sites, community health networks, and mobile outreach in closing access gaps. To that end, the introduction sets the stage for subsequent chapters that examine systemic shifts, policy headwinds, segmentation-specific insights, and practical recommendations for leaders seeking to translate evidence into impact.

How scientific advances, shifting epidemiology, and evolving procurement models are redefining treatment paradigms and supply chain resilience for neglected tropical diseases

The treatment landscape for neglected tropical diseases is undergoing transformative shifts driven by scientific innovation, demographic pressures, and changing policy environments. Advances in diagnostic sensitivity and point-of-care testing are narrowing the gap between clinical detection and timely treatment, which in turn supports more precise use of targeted therapies alongside traditional mass drug administration campaigns. At the same time, drug development pipelines have diversified to include optimized anthelmintic regimens, combination therapies, and repurposed antibiotics that can be deployed in resource-limited settings with simplified administration protocols.

Simultaneously, broader systemic dynamics are reshaping program design. Urbanization and climate variability alter vector habitats and disease transmission patterns, prompting a recalibration of intervention zones and seasonality planning. Public procurement and supply chain resilience have become focal areas, with stakeholders investing in buffer stocks, decentralized warehousing, and digital inventory systems to reduce distribution lag. Finally, partnerships between public health authorities, non-governmental organizations, and private manufacturers are expanding, enabling collaborative financing models and pooled procurement mechanisms that enhance procurement efficiency and operational scalability.

Cumulative operational and procurement consequences stemming from United States tariff adjustments in 2025 that reshaped supply chains, sourcing strategies, and inventory planning across therapeutic categories

The introduction of tariffs and trade policy changes in 2025 materially influenced procurement dynamics and supply chain configurations for essential therapeutics used in neglected tropical disease programs. Increased tariff burdens on active pharmaceutical ingredients and formulation components amplified landed costs for some drug families, prompting procurement officers to reassess supplier portfolios and prioritize localized manufacturing where feasible. In response, supply chain managers accelerated efforts to qualify alternative suppliers, diversify logistics routes, and strengthen in-region contracting to buffer against future policy volatility.

Beyond direct cost effects, tariff-induced disruption had downstream implications for program timing and inventory planning. Organizations reliant on multi-stage international supply chains encountered longer lead times and heightened compliance requirements, which required earlier ordering windows and expanded coordination across customs, regulatory, and distribution partners. Moreover, tariff impacts intersected with existing regulatory complexity for active ingredients and finished products, intensifying the need for harmonized documentation and advance engagement with national authorities. As a consequence, program teams are increasingly embedding trade-policy scenario planning into annual procurement cycles and exploring contractual terms that allocate risk more explicitly between buyers and suppliers.

Segment-driven clinical and procurement imperatives that reconcile indication-specific needs, therapeutic classes, distribution pathways, and administration modes to optimize program delivery

A nuanced understanding of the market requires segmentation by indication, product class, delivery channel, end-user setting, route of administration, and treatment approach, each of which informs clinical decision-making and operational design. When examining disease indications such as dengue, lymphatic filariasis, onchocerciasis, schistosomiasis, and trachoma, program priorities differ markedly: vector control and rapid clinical management dominate dengue responses, whereas mass drug administration and morbidity management are central to lymphatic filariasis and onchocerciasis control efforts. Schistosomiasis interventions emphasize school- and community-based chemotherapy, and trachoma programs integrate antibiotic distribution with facial cleanliness and environmental measures.

Product-level segmentation similarly shapes procurement and clinical pathways. Anthelmintics, including widely used agents such as albendazole, ivermectin, and mebendazole, remain foundational for helminth control and require formulations suitable for mass administration. Antiarthropodals and insecticides underpin vector control strategies and are procured alongside pharmaceutical products to achieve integrated intervention packages. Antibiotics such as azithromycin and doxycycline have distinct roles in trachoma and certain bacterial sequelae, influencing dosing regimens and safety monitoring. Antiprotozoals, including meglumine, pentamidine, and suramin, cater to more specialized indications and often necessitate programmatic support for parenteral administration and adverse event surveillance.

Distribution channels also determine access dynamics. Government programs and NGO distribution platforms are primary conduits for large-scale campaigns, hospital pharmacies serve as referral hubs for complex cases, and retail pharmacies offer local access for routine care and follow-up. Correspondingly, end users vary from clinics and community health centers that deliver first-line preventive measures to hospitals and mobile camps that manage severe or rapidly evolving cases. Routes of administration-oral, parenteral, and topical-interact with service delivery capacity, with oral regimens generally preferred for scale, parenteral routes reserved for severe disease, and topical formulations supporting adjunctive care.

Finally, treatment approach differentiates program design: mass drug administration is effective for community-level burden reduction and elimination objectives, while targeted therapy allows clinicians to tailor regimens according to diagnostic confirmation and individual risk profiles. Taken together, these segmentation lenses provide a multidimensional perspective that facilitates targeted procurement, optimized clinical pathways, and tailored monitoring frameworks for diverse operational contexts.

Regional operational realities and epidemiological nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that dictate adaptive treatment strategies and supply choices

Regional context significantly influences program priorities, regulatory navigation, and partnership models across the Americas, Europe Middle East & Africa, and Asia-Pacific, each presenting distinct epidemiological patterns and operational constraints. In the Americas, urbanization trends and heterogeneous health system capacities shape a dual focus on outbreak responsiveness for arboviral threats and sustained community-based control for helminth infections. Program implementers in this region often emphasize integration with primary healthcare platforms and leverage municipal health networks to extend outreach.

Across Europe, the Middle East & Africa, program responses contend with diverse regulatory environments and variable logistics infrastructure; integration of MDA campaigns with routine maternal and child health services has emerged as a pragmatic approach to broaden coverage in resource-limited settings. Humanitarian operations and cross-border coordination are particularly salient in parts of this region where displacement and conflict alter transmission dynamics and complicate supply continuity. In the Asia-Pacific, high population density in peri-urban zones, coupled with climatic influences on vector ecology, drives seasonally targeted interventions and school-based delivery models. Additionally, growing local manufacturing capacity and regional procurement consortia are enabling more resilient supply options, while digital health tools support community-level surveillance and adherence monitoring. These regional distinctions underline the importance of tailoring clinical protocols, distribution mechanisms, and partnership strategies to local realities.

How manufacturers, suppliers, and service providers are redefining competitive advantage through formulation innovation, localized production, and enhanced distribution capabilities

Industry participants and public-sector partners are adapting to a landscape where clinical efficacy, regulatory agility, and logistical competence determine competitive positioning. Pharmaceutical manufacturers focused on anthelmintics and antibiotics are investing in simplified dosing formulations and pediatric-friendly tablets to facilitate mass administration and improve adherence. At the same time, suppliers of antiarthropodals and insecticides are aligning formulations with integrated vector management programs, emphasizing safety profiles and environmental stewardship. Contract manufacturers and in-region production facilities are gaining strategic importance as stakeholders seek to reduce dependency on extended international supply chains and respond more nimbly to local demand fluctuations.

Service providers, including logistics firms and NGO implementers, are differentiating through expertise in cold-chain management for parenteral therapies, mobile outreach capabilities, and digital tracking systems that monitor campaign performance in real time. Regulatory consultancies and quality assurance partners play a critical role in accelerating product registration and ensuring compliance with national and regional standards. Collectively, these actors contribute to an ecosystem where collaboration, transparent contracting, and investment in capacity building are essential to sustain program momentum and expand access in challenging operational settings.

Practical strategic moves for leaders to strengthen program resilience, accelerate access, and align procurement and clinical strategies with local operational realities

Industry leaders and public health managers can advance impact by aligning strategic investments with operational realities and clinical priorities. First, prioritize formulation and delivery innovations that simplify administration and increase acceptability in community settings; this reduces reliance on intensive clinical infrastructure and supports higher coverage in mass drug administration contexts. Second, strengthen regional supplier networks and invest in local manufacturing partnerships to mitigate trade-policy risks and shorten lead times, while ensuring quality management systems are in place to maintain product integrity.

Third, integrate diagnostics and surveillance data into procurement and campaign planning so that targeted therapies complement mass administration where clinically appropriate; this will improve resource allocation and reduce unnecessary exposure to pharmacologic agents. Fourth, enhance supply chain transparency by adopting digital inventory and tracking solutions that enable proactive reallocation of stocks and more accurate anticipation of bottlenecks. Finally, deepen cross-sector collaborations that link public agencies, non-governmental implementers, clinical providers, and private manufacturers to coordinate financing, training, and community engagement. Taken together, these steps create a pragmatic roadmap for leaders to improve program resilience and accelerate progress against neglected tropical diseases.

A transparent methodology integrating clinical literature, implementation evaluations, regulatory analysis, and stakeholder interviews to ground operational conclusions in real-world evidence

The findings presented here synthesize multiple lines of evidence drawn from peer-reviewed clinical literature, program implementation reports, regulatory notices, and stakeholder interviews with procurement officers, clinicians, and supply chain specialists. Data synthesis prioritized recent peer-reviewed studies on treatment efficacy and safety, implementation evaluations of mass drug administration campaigns, and documented changes in trade and procurement policies. Qualitative inputs from field implementers and manufacturing partners informed assessments of operational feasibility and supply chain dynamics, providing real-world context to technical findings.

Analysis methods combined thematic synthesis for qualitative data with comparative review of regulatory and procurement practices across jurisdictions. Where applicable, triangulation between clinical evidence and operational experience guided conclusions about intervention suitability and distribution strategies. The methodology emphasized transparency in source selection, critical appraisal of evidence quality, and iterative validation with subject-matter experts to ensure that interpretations remain grounded in current practice and regulatory constraints.

Synthesis of strategic priorities that emphasize integration, localized capacity, and data-driven program design to sustain progress against neglected tropical diseases

In conclusion, the treatment landscape for neglected tropical diseases is at an inflection point where clinical advances, supply chain modernization, and adaptive policy responses must converge to sustain progress. Effective programs will blend mass drug administration with targeted clinical interventions, supported by stronger regional manufacturing capabilities, improved diagnostics, and digital tools that enhance supply chain responsiveness. Moreover, an emphasis on formulation innovation and community-centered delivery will be essential to expanding reach while preserving safety and acceptability.

Moving forward, stakeholders should prioritize cross-sector collaboration, investment in localized capacity, and integration of surveillance data into program design. By doing so, implementers and manufacturers can better anticipate disruptions, optimize resource use, and deliver treatments in ways that are both equitable and sustainable. These combined efforts will be critical to maintaining momentum against neglected tropical diseases in the years ahead.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neglected Tropical Disease Treatment Market, by Drug Type

  • 8.1. Anthelmintics
    • 8.1.1. Albendazole
    • 8.1.2. Ivermectin
    • 8.1.3. Mebendazole
  • 8.2. Antiarthropodals
  • 8.3. Antibiotics
    • 8.3.1. Azithromycin
    • 8.3.2. Doxycycline
  • 8.4. Antiprotozoals
    • 8.4.1. Meglumine
    • 8.4.2. Pentamidine
    • 8.4.3. Suramin
  • 8.5. Insecticides

9. Neglected Tropical Disease Treatment Market, by Disease Indication

  • 9.1. Dengue
  • 9.2. Lymphatic Filariasis
  • 9.3. Onchocerciasis
  • 9.4. Schistosomiasis
  • 9.5. Trachoma

10. Neglected Tropical Disease Treatment Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral
  • 10.3. Topical

11. Neglected Tropical Disease Treatment Market, by Treatment Approach

  • 11.1. Mass Drug Administration
  • 11.2. Targeted Therapy

12. Neglected Tropical Disease Treatment Market, by End User

  • 12.1. Clinics
  • 12.2. Community Health Centers
  • 12.3. Hospitals
  • 12.4. Mobile Camps

13. Neglected Tropical Disease Treatment Market, by Distribution Channel

  • 13.1. Government Programs
  • 13.2. Hospital Pharmacy
  • 13.3. NGO Distribution
  • 13.4. Retail Pharmacy

14. Neglected Tropical Disease Treatment Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Neglected Tropical Disease Treatment Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Neglected Tropical Disease Treatment Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Neglected Tropical Disease Treatment Market

18. China Neglected Tropical Disease Treatment Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Amgen Inc.
  • 19.7. Astellas Pharma Inc.
  • 19.8. AstraZeneca plc
  • 19.9. Bayer AG
  • 19.10. Boehringer Ingelheim International GmbH
  • 19.11. Bristol-Myers Squibb Company
  • 19.12. Cipla Limited
  • 19.13. Eisai Co., Ltd.
  • 19.14. Eli Lilly and Company
  • 19.15. Gilead Sciences, Inc.
  • 19.16. GlaxoSmithKline plc
  • 19.17. Glenmark Pharmaceuticals Ltd.
  • 19.18. Hansa Biopharma AB
  • 19.19. Johnson & Johnson Services, Inc.
  • 19.20. Merck & Co., Inc.
  • 19.21. Mylan N.V.
  • 19.22. Novartis AG
  • 19.23. Otsuka Pharmaceutical Co., Ltd.
  • 19.24. Pfizer, Inc.
  • 19.25. Regeneron Pharmaceuticals, Inc.
  • 19.26. Sanofi S.A.
  • 19.27. Serum Institute of India Pvt. Ltd.
  • 19.28. Sumitomo Dainippon Pharma Co., Ltd.
  • 19.29. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ALBENDAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ALBENDAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ALBENDAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY IVERMECTIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY IVERMECTIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY IVERMECTIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEBENDAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEBENDAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEBENDAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIARTHROPODALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIARTHROPODALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIARTHROPODALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY AZITHROMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY AZITHROMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY AZITHROMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DOXYCYCLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DOXYCYCLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DOXYCYCLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEGLUMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEGLUMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEGLUMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PENTAMIDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PENTAMIDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PENTAMIDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SURAMIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SURAMIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SURAMIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY INSECTICIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY INSECTICIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY INSECTICIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DENGUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DENGUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DENGUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY LYMPHATIC FILARIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY LYMPHATIC FILARIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY LYMPHATIC FILARIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ONCHOCERCIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ONCHOCERCIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ONCHOCERCIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SCHISTOSOMIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SCHISTOSOMIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SCHISTOSOMIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TRACHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TRACHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TRACHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MASS DRUG ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MASS DRUG ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MASS DRUG ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MOBILE CAMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MOBILE CAMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MOBILE CAMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GOVERNMENT PROGRAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GOVERNMENT PROGRAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GOVERNMENT PROGRAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY NGO DISTRIBUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY NGO DISTRIBUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY NGO DISTRIBUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2032 (USD MILLION)
  • TABLE 199. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 200. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2032 (USD MILLION)
  • TABLE 201. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 202. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 204. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2032 (USD MILLION)
  • TABLE 229. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 230. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2032 (USD MILLION)
  • TABLE 231. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 232. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 234. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2032 (USD MILLION)
  • TABLE 239. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 240. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2032 (USD MILLION)
  • TABLE 241. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 242. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 244. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)